New York: Saunders Elsevier
Primary and secondary endpoints Primary endpoints of the present study were changes in % FMD, IMT, PAI-1, VCAM-1, MCP-1, BNP, hs-CRP, IL-6, TNF-, endothelin, E-selectin and resistin while the secondary endpoints were the changes in serum levels of adiponectin, leptin, total cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride
43, 44 Urotensin-II has also been shown to function as a potent vasodilator in some isolated vessels
Apply daily without skipping
By activating multiple pathways involved in appetite regulation, insulin sensitivity and energy expenditure, It produces stronger metabolic effects than earlier generations of weight loss medications